Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis

被引:53
作者
Yang, Baojuan [1 ]
Zhu, Lin [2 ]
Cheng, Haiyan [1 ]
Li, Qi [1 ]
Zhang, Yunyan [1 ]
Zhao, Yashuang [2 ]
机构
[1] Harbin Med Univ, Canc Hosp, Dept Gynecol Oncol, Harbin, Heilongjiang Pr, Peoples R China
[2] Harbin Med Univ, Coll Publ Hlth, Dept Epidemiol, Harbin, Heilongjiang Pr, Peoples R China
关键词
IMRT; 3D-CRT; DVH; Gynecologic malignancies; Meta-analysis; WHOLE PELVIC RADIOTHERAPY; ACUTE HEMATOLOGIC TOXICITY; ADVANCED CERVICAL-CANCER; RADIATION-THERAPY; CONCURRENT CISPLATIN; PROSTATE-CANCER; BONE-MARROW; GASTROINTESTINAL TOXICITY; DOSE-ESCALATION; EXTENDED-FIELD;
D O I
10.1186/1748-717X-7-197
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To quantitatively evaluate the safety and related-toxicities of intensity modulated radiotherapy (IMRT) dose-volume histograms (DVHs), as compared to the conventional three-dimensional conformal radiotherapy (3D-CRT), in gynecologic malignancy patients by systematic review of the related publications and meta-analysis. Methods: Relevant articles were retrieved from the PubMed, Embase, and Cochrane Library databases up to August 2011. Two independent reviewers assessed the included studies and extracted data. Pooled average percent irradiated volumes of adjacent non-cancerous tissues were calculated and compared between IMRT and 3D-CRT for a range of common radiation doses (5-45Gy). Results: In total, 13 articles comprised of 222 IMRT-treated and 233 3D-CRT-treated patients were included. For rectum receiving doses >= 30 Gy, the IMRT pooled average irradiated volumes were less than those from 3D-CRT by 26.40% (30 Gy, p = 0.004), 27.00% (35 Gy, p = 0.040), 37.30% (40 Gy, p = 0.006), and 39.50% (45 Gy, p = 0.002). Reduction in irradiated small bowel was also observed for IMRT-delivered 40 Gy and 45 Gy (by 17.80% (p = 0.043) and 17.30% (p = 0.012), respectively), as compared with 3D-CRT. However, there were no significant differences in the IMRT and 3D-CRT pooled average percent volumes of irradiated small bowel or rectum from lower doses, or in the bladder or bone marrow from any of the doses. IMRT-treated patients did not experience more severe acute or chronic toxicities than 3D-CRT-treated patients. Conclusions: IMRT-delivered high radiation dose produced significantly less average percent volumes of irradiated rectum and small bowel than 3D-CRT, but did not differentially affect the average percent volumes in the bladder and bone marrow.
引用
收藏
页数:11
相关论文
共 47 条
[41]  
Saw C B, 2001, Med Dosim, V26, P111, DOI 10.1016/S0958-3947(01)00065-6
[42]  
Sirak I, 2010, Ceska Gynekol, V75, P177
[43]   Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy [J].
Vargas, C ;
Martinez, A ;
Kestin, LL ;
Yan, D ;
Grills, I ;
Brabbins, DS ;
Lockman, DM ;
Liang, J ;
Gustafson, GS ;
Chen, PY ;
Vicini, FA ;
Wong, JW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (05) :1297-1308
[44]   Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer [J].
Vora, Sujay A. ;
Wong, William W. ;
Schild, Steven E. ;
Ezzell, Gary A. ;
Halyard, Michele Y. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (04) :1053-1058
[45]   Organisational Standards for the Delivery of Intensity-modulated Radiation Therapy in Ontario [J].
Whitton, A. ;
Warde, P. ;
Sharpe, M. ;
Oliver, T. K. ;
Bak, K. ;
Leszczynski, K. ;
Etheridge, S. ;
Fleming, K. ;
Gutierrez, E. ;
Favell, L. ;
Green, E. .
CLINICAL ONCOLOGY, 2009, 21 (03) :192-203
[46]   DOES THE PEACOCK HAVE ANYTHING TO DO WITH RADIOTHERAPY [J].
WOO, SY ;
SANDERS, M ;
GRANT, W ;
BUTLER, EB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (01) :213-214
[47]  
Yeoh Eric, 2008, Curr Opin Support Palliat Care, V2, P40, DOI 10.1097/SPC.0b013e3282f4451f